Clin Mol Hepatol.
2024 Oct;30(4):721-723. 10.3350/cmh.2024.0443.
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
- Yu J
1
- Affiliations
-
- 1State key laboratory of natural medicine, China Pharmaceutical University, Nanjing, China
- KMID: 2560080
- DOI: http://doi.org/10.3350/cmh.2024.0443
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
- Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
- Thyroid Hormone-Mediated Selective Autophagy and Its Implications in Countering Metabolic Dysfunction-Associated Steatotic Liver Disease
- Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights
- The Role of Macrophage Lipophagy in Reverse Cholesterol Transport
